Infectious complications associated with alemtuzumab treatment

13504 Introduction: We report our single institutional experience of ICs associated with alemtuzumab treatment. Methods: Patients (pts) who received alemtuzumab were identified by review of the GUH pharmacy database. All ICs occurring from initiation of alemtuzumab until death or end of follow up as of January 3, 2007 were reviewed and categorized as opportunistic (OI) or non- opportunistic (NOIs). Pts who received hematopoetic stem cell or solid organ transplantation subsequent to alemtuzumab (n=33) or who could not tolerate test doses of alemtuzumab (n=1) were excluded from analysis. Results: Data were reviewed for 16 pts treated with alemtuzumab from February 2003 to September 2006. Median age was 60 years (range 40–78); with 4 females and 12 males. Fifteen pts had chronic lymphocytic leukemia (CLL), and 1 had acute lymphoblastic leukemia (ALL). Median follow-up after starting alemtuzumab treatment was 462 days. Pts with CLL had an average of 2.4 prior treatments (range 1–6). The pt with ALL received a...